2. 您的位置
3. 首页
4. 会议论文
5. Erlotinib as Neoadjuvant Treatment in Endobronchial Ultrasound Confirmed Stage ⅢA-N2 Non-small Cell

Erlotinib as Neoadjuvant Treatment in Endobronchial Ultrasound Confirmed Stage ⅢA-N2 Non-small Cell

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户：jeffyi2009

【摘 要】

：

　　Background: Concurrent chemoradiation therapy or induction chemotherapy plus surgery were considered as standard treatment to non-small-cell lung cancer (NS

【作 者】

：

BaohuiHan;LiwenXiong;JiayuanSun;RongLi;YuqingLou;YanweiZhang;AiqingGu;LiyanJiang;JianxinShi;WentaoFang;HengZha; 

【机 构】

：

Lung Cancer, Shanghai Chest Hospital affiliated to Shanghai Jiaotong University

【出 处】

：

第十八届全国临床肿瘤学大会暨2015年CSCO学术年会

【发表日期】

：

2015年期

下载到本地 , 更方便阅读

下载此文 赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

　　Background: Concurrent chemoradiation therapy or induction chemotherapy plus surgery were considered as standard treatment to non-small-cell lung cancer (NSCLC) in stage ⅢA-N2, but the side effect became the obstacle for most patients to be treated and cause poor clinical outcome.

其他文献

Retrospective analysis of efficacy of gefitinib in non small cell lung cancer

　　Objective: The primary end points of this study are: 1.Overall Survival in patients of NSCLC on gefitinib.The secondary end points of this study are: 2.Prog

会议

DNA repair protein APE 1 is a novel biomarker to predict platinum resistance in non-small cell lung

　　Objective: As one of the major cancers with a high mortality rate, lung cancer is still a huge health challenge worldwide.Although platinum-based doublet ch

会议

Determining the prevalence of EGFR mutations in patients with advanced non-small-cell lung cancer (a

　　Objective: IGNITE (a large, multinational, diagnostic, non-comparative, interventional study;NCT01788163) assessed EGFR mutation frequency in patients with

会议

PD-L1 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non-Small C

　　Objective: Although neoadjuvant chemotherapy (NAC) for advanced lung cancer can improve operability and local disease control, the duration of benefit is li

会议

Progression of central nervous system metastases in advanced non-small cell lung cancer effectively

　　Objective: Central nervous system (CNS) progression is frequently detected in patients with favorable initial responses to Epidermal Growth Factor Receptor-

会议

Pooled analysis of CNS response to alectinib in two phase 2studies of pre-treated ALK+ NSCLC

　　Objective: The central nervous system (CNS) is a frequent site of progression in ALK+ NSCLC patients treated with crizotinib, thus good CNS efficacy is of c

会议

Genome-wide screen of DNA methylation changes reveals GABBR2 as a novel potential treatment target f

　　Objective: Lung cancer is the leading cause of cancer related death in the world.The last decade has witnessed the rapid development of epidermal growth fac

会议

CACNA2D1 Is a Novel Biomarker for Tumor Initiating Cells and Has Therapeutic Effect in Non-Small Cel

　　Objective: Tumor initiating cells (TICs) are a small subpopulation within cancer that is thought to be resistant to conventional therapiesand capable of rei

会议

Two-stage induced differentiation of OCT4+/Nanog+ stem-like cells in lung adenocarcinoma

　　Objective: Stem-like cells in solid tumors are purported to contribute to cancer development and poor treatment outcome.The abilities to self-renew, differe

会议

Prognostic Factors in Resected Pathological Right Middle Lobe Non-Small Cell Lung Cancer

　　Objective: Patients (pts) with right middle lobe non-small cell lung cancer (NSCLC) were not well studied.This study analyzed the prognostic factors in rese

会议